Minichromosome Maintenance (MCM) Family as potential diagnostic and prognostic tumor markers for human gliomas

Cong Hua1†, Gang Zhao1†, Yunqian Li1† and Li Bie1,2*

Abstract
Background: Gliomas are the most common type of all central nervous system tumors. Almost all patients diagnosed with these tumors have a poor prognostic outcome. We aimed to identify novel glioma prognosis-associated candidate genes.

Methods: We applied WebArrayDB software to span platform integrate and analyze the microarray datasets. We focused on a subset of the significantly up-regulated genes, the minichromosome maintenance (MCM) family. We used frozen glioma samples to predict the relationship between the expression of MCMs and patients outcome by qPCR and western blot.

Results: We found that MCMs expression was significantly up-regulated in glioma samples. MCM2-7 and MCM10 expressions were associated with WHO tumor grade. High MCM2 mRNA expression appeared to be strongly associated with poor overall survival in patients with high grade glioma. Furthermore, we report that MCM7 is strongly correlated with patient outcome in patients with WHO grade II-IV tumor. MCM3 expression was found to be up-regulated in glioma and correlated with overall survival in patients with WHO grade III tumor. MCM2, MCM3 and MCM7 expression levels were of greater prognostic relevance than histological diagnosis according to the current WHO classification system.

Conclusions: High expression of MCM 2, MCM3 and MCM7 mRNA correlated with poor outcome and may be clinically useful molecular prognostic markers in glioma.

Keywords: Glioma, MCMs, Tumor marker, Prognosis

Background
Gliomas are one of the most common malignant tumors of the central nervous system. Gliomas represent a group of low grade and high grade brain tumors that originate from glial cells. Most are characterized by diffuse infiltrative growth in the surrounding brain. According to the 2007 WHO grading system [1], these tumors are classified as typical WHO grade I-IV. The median survival for patients with anaplastic astrocytoma (WHO grade III) and glioblastoma (WHO grade IV) is less than three years and less than one year, respectively [2]. The prognosis remains poor despite extensive research and advances in radiation therapy and chemotherapeutic regimes [3]. All types of cancer as well as glioma constitute a major public health problem that presents several challenges to researchers such as identification of biomarkers for improved and early diagnosis, classification of tumors, and the definition of targets for more effective treatment. Genetic analysis over the past 30 years has defined the major mutational targets in the human genome that are associated with the formation of glioma [4]. Moreover, large-scale association genome-wide surveys have been used to identify new biomarkers that have been developed as diagnostic and prognostic tools.

In this study, to unravel molecular glioma tumorigenesis and discover novel molecular biomarkers for diagnostic...
and/or prognostic purposes, we apply WebArrayDB software (www.WebArrayDB.org) to span platform integrate and analyze the microarray datasets [5-7], including data stored at the Cancer Genome Anatomy Project (http://cgap.nci.nih.gov/Genes).

Among the genes up-regulated in gliomas, we focused on a subset of the significantly up-regulated genes, the minichromosome maintenance (MCM) family. The MCM family includes eight members: MCM2-MCM7 and MCM10 [8]. They are considered to function as licensing components for the S-phase of cell cycle [9]. MCMs can be expressed in abundance in different cell cycles and degraded in quiescence, senescence and differentiation steps thus they can be used as specific markers of the cell cycle state in tissues [10]. This feature of MCM genes in proliferating cells has led to their potential clinical application as a marker for cancer screening [11].

Here we report that MCM family genes are almost up-regulated in 59 human glioma tumor samples compared to six normal brain controls by qRT-PCR. Our study indicates for the first time that high MCM2 mRNA expression appears to be strongly associated with poor overall survival in high grade glioma. Furthermore, we report that MCM7 is strongly correlated with patient outcome in WHO grade II-IV. MCM3 expression found to be up-regulated in glioma and correlated with overall survival in WHO grade III. MCM2, MCM3 and MCM7 expression level were of greater prognostic relevance than histological diagnosis according to the current WHO classification system. Interestingly, in the last few years, studies have pointed out the roles of MCM family members as diagnostic and prognostic markers for several malignancies [12].

Methods
Patients and tumor samples
A total of 59 glioma specimens were obtained from the Department of Neurosurgery, First Affiliated Hospital of Jilin University, from 2003 to 2012. The samples included 21 females and 38 males and an age range 2–69 years. Samples were collected immediately after surgical resection, snap frozen, and stored at −80°C until used for RNA extraction. All gliomas were samples of primary tumor before therapy. All cases had been diagnosed at the primary hospital by neuropathologists. Original pathology slides were obtained and reviewed blinded to the original diagnosis according to the 2007 WHO classification (14 II grade, 21 III grade and 24 IV grade). The samples consisted of astrocytoma (n = 27), anaplastic astrocytoma (n = 9) and glioblastoma (n = 23). Six control samples (normal brain) were obtained from the Department of Neurosurgery, First Affiliated Hospital of Jilin University from patients undergoing surgery for brain trauma (n = 4) and epilepsy (n = 2). They were all reviewed to verify the absence of tumor. Written informed consent for participation in the study was obtained from all participants or their guardians. The study was approved by the Institutional Review Board (IRB) of The First Hospital of Jilin University (IRB00008484).

RNA isolation and quality evaluation
Total RNA was extracted from frozen sections with the TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s protocol. Total RNA yield was measured with an A260/280 ratio of 1.7-1.9, demonstrating purity. Quality was evaluated on nanochips with the Bio-Rad Experion automated electrophoresis system (Bio-Rad Laboratories, Hercules, CA, USA). Samples had a 28S/18S ratio of 1.5 and did not show evidence of ribosomal peak degradation.

Real-time quantitative reverse transcription PCR
About 500 ng total RNA from each sample was reverse transcribed with SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). Primers were designed with AlleleID Version 7.0 software (Premierbiosoft, Palo Alto, CA, USA). Predesigned gene expression assays were obtained from Integrated Device Technology (IDT, San Diego, CA, USA). Real-time quantitative PCR was then carried out using an ABI Prism 7900 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA). A quantity of 15 ng of cDNA was used in a 25 μl PCR reaction containing the appropriate primers and 1 × SYBR Green PCR Super mix (BioPioneer, San Diego, CA, USA). All products were 77 to 134 bp. Dissociation curves of each sample were used to check the specificity of amplification. PCR reactions were examined by 1.6% agarose gel electrophoresis for verification of dissociation curve results. Parallel experiments were carried out using an 18S rRNA and HPRT1 primer set. qPCR reactions were performed in triplicate, and the relative fold changes were calculated with the Pfaffl method [13] for each gene corrected using 18S rRNA + HPRT1[14]. All primer pairs utilized in this study presented amplification efficiency between 91-110% (Additional file 1).

Western blot
To detect MCM2, MCM3 and MCM7 protein in glioma tumors, we examined six glioma samples (two each of WHO stages II, III, IV). The protein concentration of cell lysates was determined by the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer’s instructions. Thirty micrograms of protein per tissue lysate was electrophoresed on 7-12% gels and transferred to a polyvinylidene difluoride membrane filter (Millipore, Billerica, MA, USA). Blots were
probed with the appropriate antibody. Quantitative determination of the protein was assessed by densitometric scanning of the band from film. An Alphalager 2000 Documentation and Analysis System (Alpha Innotech Corp, San Leandro, CA, USA) was used to quantify bands of appropriate sizes.

The following primary antibodies were used: anti-β-actin (Sigma Chemical Co, St. Louis MO, USA), anti-MCM2 (sc-10771, Santa Cruz Biotechnology, USA), anti-MCM3 (sc-9849, Santa Cruz Biotechnology, USA), and anti-MCM7 (sc-22782, Santa Cruz Biotechnology, USA).

**Statistical analysis**

The statistical significance of differences in the means was calculated using the ANVOA test. To identify a model describing the relationship between survival and the MCMs mRNA expression, the functional form of the relationship was tested by maximally selected log-rank statistics as previously described [15]. The resulting model was applied in further survival analyses. Multivariate Cox regression was used to investigate the prognostic power of candidate gene expression adjusting for established prognostic variables. The Cox proportional hazards regression were carried out with the use of the design and survival package of the R software environment. Overall survival curves (from diagnosis to death) were obtained using the Kaplan-Meier method and compared with a log-rank test. A $p$ value of less than 0.05 was considered to indicate statistical significance.

**Results**

**Up-regulation of the MCM family expression in human glioma samples**

The mRNA expression level of the MCM family members was examined in 59 human glioma samples and six normal brain tissues by qPCR (n = 3), normalized to 18S rRNA and HPRT1 levels. We found a significant increase in MCM2 (3.5 fold), MCM3 (3.1 fold), MCM4 (4.3 fold), MCM5 (3.8 fold), MCM6 (3.5 fold), MCM7 (3.0 fold) and MCM10 (3.6 fold) expressions in tumor tissues (the average fold value of three grades) compared to the normal brain controls. Moreover, as shown in Table 1, we observed that MCM3-MCM5,MCM7 and MCM10 were significantly changed between grade II, III and IV samples ($p < 0.05$). MCM2 and MCM6 were significantly increased between grade II (low grade) and III-IV (high grade) samples ($p < 0.05$). Four independent external microarray datasets (8 normal, 29 stage II, 116 stage III and 618 stage IV, Additional file 2) were analyzed using the WebArrayDB cross-platform analysis suite to validate our experiment results. Genes were sorted in ascending order according to the $p$ values for WHO grade, after taking into account gender and patient age as variables. Expression of MCM family members was highly correlated with glioma grade (Table 1). To confirm the specificity of the qPCR results, we characterized MCM2, MCM3, MCM7, as well as β-actin as a loading control, in six glioma samples for which freshly frozen materials were available. As shown in Figure 1, an immunoreactive band of MCM2, MCM3 and MCM7 were seen in all six cases of gliomas, MCM2, MCM3 and MCM7 expressions were significantly higher in malignant tissues than in tissues with low malignant potential.

**Multivariate survival analysis of prognostic parameters**

Multivariate survival analysis identified high expression of MCM2 as an independent prognostic factor for survival time, as well as MCM3 and MCM7 ($p < 0.05$), (Table 2).

**The MCMs expression correlates with poor outcome in patients with glioma**

We reviewed each grade of tumor separately and investigated whether the expression of MCM2, MCM3 and MCM7 predicts patient survival within each subgroup. The search for a model describing the relationship between survival and expression of MCM family genes expression using maximally selected log-rank statistics identified a cutoff model to be most suitable: MCM2 (fold change cutoff for stage II 2.3, III 4.7, and IV 5.6), MCM3(II 2.4, III 3.1, and IV 5.3) and MCM7 (II 1.6, III 4.6, and IV 6.1). The qPCR cutoff ratios were used to separate two patient subgroups with significantly different outcomes [maximally selected log rank statistics, $p < 0.05$ (overall survival)]. Applying these MCM family expression cutoff to Kaplan-Meier survival curve estimation revealed decreased survival probability for patients with tumor expressing high levels of MCM2, MCM3 and MCM7 ($p < 0.05$), (Figure 2). In the grade II group, MCM7 expression appeared to be a strongly positive prognostic factor ($p < 0.01$). In the grade III group, better prognosis was found for patients with glioma with high expression of three genes compared to patients with high expression ($p < 0.01$). MCM2 and MCM7 expression appeared to be prognostic factors in the grade IV group, although they are not strongly positive in any of these cases ($p < 0.05$). Thus the expression level of MCM2, MCM3 and MCM7 reveal information on the survival probability for patients with glioma beyond that revealed by grade alone.

The result was validated by GBM database. Repository of Molecular Brain Neoplasia Data (Rembrandt, https://caintegrator.nci.nih.gov/rembrandt/), a cancer clinical genomics database and a Web-based data mining and analysis platform aimed at facilitating discovery by connecting
| Gene    | Unique ID | Gene origin | Fold | p value | Gene origin | Fold | p value |
|---------|-----------|-------------|------|---------|-------------|------|---------|
| MCM2    | 202107_s_at | qRT-PCR | 1.91 | 3.9 | 4.22 | 2.04 | 2.21 | 1.08 | 3.5 | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
|         |           | Microarray | 1.61 | 3.68 | 5.39 | 2.16 | 3.16 | 1.47 |     | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
| MCM3    | 201555_at  | qRT-PCR | 1.59 | 3.01 | 4.46 | 1.89 | 2.81 | 1.49 | 3.1 | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
|         |           | Microarray | 1.92 | 2.32 | 2.79 | 1.26 | 1.52 | 1.2  |     | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
| MCM4    | 222036_s_at | qRT-PCR | 2.41 | 4.56 | 6.15 | 1.89 | 2.55 | 1.35 | 4.3 | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
|         |           | Microarray | 0.81 | 1.51 | 1.61 | 1.58 | 1.69 | 1.07 |     | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
| MCM5    | 201755_at  | qRT-PCR | 1.91 | 4.25 | 4.48 | 2.22 | 2.34 | 1.05 | 3.8 | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
|         |           | Microarray | 0.57 | 1.95 | 2.46 | 2.03 | 2.57 | 1.26 |     | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
| MCM6    | 201930_at  | qRT-PCR | 1.28 | 4.8  | 4.63 | 3.76 | 3.62 | 0.96 | 3.5 | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
|         |           | Microarray | 2.24 | 2.63 | 3.05 | 2.07 | 2.4  | 1.16 |     | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
| MCM7    | 208795_s_at | qRT-PCR | 1.51 | 3.29 | 4.33 | 2.17 | 2.86 | 1.32 | 3.0 | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
|         |           | Microarray | 1.02 | 2.23 | 2.08 | 1.79 | 1.67 | 0.93 |     | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
| MCM10   | 220651_s_at | qRT-PCR | 2.58 | 3.86 | 4.73 | 1.5  | 1.83 | 1.22 | 3.6 | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |
|         |           | Microarray | 6.18 | 26.21 | 31.81 | 3.54 | 4.29 | 1.21 |     | II → Normal | III → Normal | IV/Normal | III/II | IV/III | (II-IV)/Normal |

MCM3 and MCM7, and MCM10 were significantly different between grade II, III and IV samples (p < 0.05). MCM2 and MCM6 expressions were significantly increased between grade II (low grade) and III-IV (high grade) samples (p < 0.05).
the dots between clinical information and genomic characterization data. The microarray data are available for 181 GBM samples in Rembrandt database. MCM2 and MCM3 were not correlate with the prognosis of GBM patients ($p > 0.05$). When the cut-off point was the up-regulation of 2 fold, MCM7 was significant relative to the outcome of GBM patients ($p < 0.01$), (Table 3).

**Discussion**

Glioma tumors are the most common and deadly brain tumors. However, the survival of patients with low grade (stage II) glioma is significantly higher than that of patients with high grade (stage III-IV) tumors. In the study, we applied WebArrayDB software (www.WebArrayDB.org) to analysis three independent microarray datasets which come from different microarray platforms. We focused on the part of the members of the MCM gene family most highly significantly up-regulated in gliomas.

MCMs were first discovered in the mutants of the yeast Saccharomyces cerevisiae that had defects in maintaining a simple minichromosome [16]. MCM 2–7 form a heterohexamer complex [17]. The MCM protein complex is associated with the origins of DNA replication to form part of the pre-replicative complex. Activation of MCM complex by cyclin-dependent kinases, such as Cdc6, Cdt1 andDbf4/Cdc7, leads to initiation of DNA synthesis [18]. The hexameric MCM component of the pre-replicative complex exhibits helicase activity that may make DNA unwind during replication [11]. Thus, MCM proteins allow the DNA replication machinery to access binding sites on DNA [19]. Several studies suggested that increased levels of MCMs can identify not only malignant cells [20-25] but also precancerous cells and tumor recurrence [26-28], indicating that they might also serve as prognostic tumor markers. The last member, MCM10, may have a dual function: firstly to stabilize DNA polymerase-α-primase and secondly to target it to chromatin [29].

Recent studies have proven that MCMs expression has a relationship with diagnosis and prognosis. MCM2 and MCM3 seem to have the most important role in several types of neoplasia, including alimentary system tumors [30-35], genitourinary system tumors [36-41], lung cancer [42,43], breast cancer [44-47], and meningioma [27,48]. Moreover, several investigators have found that the measurement of MCM6 protein expression is a good diagnostic marker for chondrosarcoma [49], and lymphoma [50]. MCM2, MCM3 and MCM7 proteins expression is also known to be an important tool for estimating tumor proliferation and a useful adjunct to the routinely used proliferation markers for glioma diagnosis [51-56].

Moreover, in past research, MCMs have also provided useful information on outcome of patients with glioma. Wharton et al. found that cases with a high MCM2 labeling index had a poorer prognosis than those with a low index in patients with oligodendroglioma [51]. Scott et al. reported that the cyclin A: MCM2 labeling fraction might predict a relatively favorable response to radical radiotherapy in patients with glioblastoma [52]. Söling et al. in their series of patients with astrocytoma found that high MCM3 expression is an independent predictor of poor outcome [53].

Compared with previous reports, we confirmed MCM2, MCM3 and MCM7 expression were correlated with

| Parameter       | Risk ratio | 95% CI   | $p$  |
|-----------------|------------|----------|------|
| Sex             | 2.067      | 0.789-4.670 | 0.151|
| Age (≥40)       | 3.155      | 1.984-4.039 | 0.042|
| WHO (Grade 4)   | 3.0843     | 1.523-3.810 | 0.034|
| MCM2            | 8.519      | 6.280-10.508 | 0.004|
| MCM3            | 7.328      | 5.102-9.833 | 0.007|
| MCM4            | 0.506      | 0.843-1.441 | 0.477|
| MCM5            | 2.117      | 0.946-3.127 | 0.146|
| MCM6            | 2.873      | 1.377-4.073 | 0.090|
| MCM7            | 6.576      | 4.114-8.243 | 0.010|
| MCM10           | 0.029      | 0.015-1.093 | 0.937|

![Figure 1 Expression of MCM2, MCM3 and MCM7 protein in gliomas by Western blot. A western blots of six glioma samples (WHO grade II, III and IV). B Quantitation of the western blots by using β-actin as the loading control.](http://www.biomedcentral.com/1471-2407/14/526)
WHO grading of glioma tumors on mRNA profiles by microarray data analysis and qPCR. The result of western blot also validated this finding. Some studies reported positive correlations in the expression of MCMs with Ki67 [44,47,57]. Moreover, several studies have revealed that MCMs are characterized by higher specificity and sensitivity than other conventional proliferative markers [58,59]. Ki-67 is a crucial molecular marker for estimating the progression and prognosis of gliomas [60,61]. Despite the fact that MCMs and Ki67 have a similar expression pattern during many cell cycle phases (G1, S, G2, and M phases), detailed cell-cycle analysis shows differences between both markers. Ki67 is absent during the early G1 phase, whereas MCMs are expressed in the entire G1 phase. As such, the degree of tumor cell proliferation may be better reflected by using MCMs.

Kaplan-Meier analysis showed that MCM2, MCM3 and MCM7 can function as an independent prognostic indicator for overall survival (p < 0.05). Our study indicates for the first time that high MCM2 mRNA expression appears to be strongly associated with poor overall survival in high grade glioma. MCM3 expression was found to be up-regulated in glioma and correlated with overall survival in the grade III group. However, MCM3 does not appear to be a predictor of survival in the patients of the grade IV group. Söling et al. have also reported results supporting this conclusion [53]. Likewise, MCM2 and MCM3 expression in grade II group does not appear to be a significant predictor, although this might be explained by the limited sample size. Furthermore, we report that MCM7 was correlated with patient outcome in grade II-IV group. Erkan EP et al. also report MCM7 was the significant up-regulate gene in GBM samples compared with normal white matter tissues. Moreover, siRNA-mediated knockdown of MCM7 expression reduced GBM cell proliferation and also inhibited tumor growth in both xenograte and orthotopic mouse models of GBM [56].

**Conclusions**

In conclusion, the results suggest that MCM2, MCM3 and MCM7 play important roles in glioma tumor progression. Most notably, MCM2, MCM3 and MCM7 aberrations in glioma tumors portend a particularly aggressive clinical behavior.

### Table 3 Comparison of mRNA expression of MCM2, MCM3 and MCM7 in glioma tumor tissue by microarray analysis (Rembrandt, https://caintegrator.nci.nih.gov/rembrandt/)

| Gene | Unique ID | Gene origin | Number of samples (all upregulate) | Fold | Cut-off point | p value |
|------|-----------|-------------|-----------------------------------|------|--------------|---------|
|      |           |             | Group 1  | Group 2  |               |         |
| MCM2 | 202107_s_at | Microarray  | 133     | 48       | 2.0           | 0.181   |
| MCM3 | 201555_at  | Microarray  | 138     | 43       | 2.0           | 0.417   |
| MCM7 | 208795_s_at | Microarray  | 59      | 122      | 3.0           | 0.009   |

p < 0.05. MCM2 and MCM3 were not correlate with the prognosis of GBM patients (p > 0.05). When the cutoff point was the up-regulation of 3fold, MCM7 was significant correlate with the outcome of GBM patients (p < 0.01).


Additional files

Additional file 1: Primer sequences and amplification summary.
Additional file 2: The other most up-regulated 20 genes.

Abbreviations

MCM, Minichromosome maintenance; GBM, Glioblastoma; qRT-PCR, Quantitative real-time reverse transcription polymerase chain reaction assay; TCGA, The Cancer Genome Anatomy; Rembrandt: Repository of Molecular Brain Neoplasia Data; OS, Overall survival.

Competing interests

The authors have no conflict of interest to declare.

Authors’ contributions

CH, GZ and YQL carried out the molecular genetic studies, and participated in the preparation of the manuscript. LB conceived the study, and participated in its design and coordination and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81201980) and Natural Science Foundation of Jilin Province, China (No. 20135202208JH).

Received: 13 May 2014 Accepted: 15 July 2014 Published: 21 July 2014

References

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114(2):197–109.
2. DeAngelis LM: Brain tumors. N Engl J Med 2001, 344(21):14–123.
3. Jermal A, Murray T, Word E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005, 55(1):1–30.
4. Van Meir EG, Hadijanpoysig C, Norden AD, Shu HK, Wen PY, Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010, 60(3):166–193.
5. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF: Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004, 64(18):6503–6510.
6. Gravendeel LA, Kouvosenhoven MC, Geurts O, de Rocci J, Stubbis AP, Dujin JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, De Moor B, Eilers PH, van der Spek PJ, Krom JM, Sillevits SMF, van den Bent MJ, French PJ: Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009, 69(23):9065–9072.
7. Wong KK, Chang YM, Tsang YT, Perlaky L, Su J, Adesina A, Armstrong DL, Williams ED, Williams GH: Enhanced expression of MCM proteins in cancer cells derived from uterine cervix. Eur J Biochem 2003, 270(8):1089–1101.
8. Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, Weinberg V, Carroll PR, Tisty TD: Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res 2001, 7(9):2712–2718.
9. Rannath N, Hernandez FJ, Tan DF, Huberman JA, Natarajan N, Beek AF, Hyland A, Todorov IT, Brooks JS, Bepler G: MCM-2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 2001, 19(22):4259–4266.
10. Rodins K, Cheale M, Coleman N, Fox SB: Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. Clin Cancer Res 2002, 8(4):1075–1081.
11. Alison MR, Hunt T, Forbes SJ: Minichromosome maintenance (MCM) proteins may be pre-cancer markers. Gut 2002, 50(3):290–291.
12. Hunt DP, Freeman A, Morris LS, Burnet NG, Bird K, Davies TW, Laskey RA, Coleman N: Early recurrence of benign meningioma correlates with expression of minichromosome maintenance-2 protein. Br J Neurosurg 2002, 16(1):10–15.
13. Tan DF, Huberman JA, Hyland A, Loewen GM, Brooks JS, Beek AF, Todorov IT, Bepler G: MCM2—a promising marker for premalignant lesions of the lung: a cohort study. BMC Cancer 2001, 1.
14. Ricke RM, Blieski AJ: MCM10 regulates the stability and chromatin association of DNA polymerase-alpha. Mol Cell 2004, 16(2):173–185.
15. Tokuyasu N, Shomori K, Nishihara K, Kawaguchi H, Fujioka S, Yamaga K, Ikekuchi M, Ito H: Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: clinicopathological significance. Gastric Cancer 2008, 11(1):37–46.
16. Scott IS, Morris LS, Bird K, Davies RJ, Vowler SL, Rushbrook S, Marshall AE, Laskey RA, Miller A, Arends MJ, Coleman N: A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: Implications for the prediction of outcome in colorectal cancer. J Pathol 2003, 201(2):187–197.
17. Guzinska-Ustymowicz K, Stepien E, Kemona A: MCM-2, Ki-67 and PCNA protein expressions in pT3G2 colorectal cancer indicated lymph node involvement. Anticancer Res 2008, 28(1B):451–457.
18. Giaginis C, Georgiadou M, Dimakopoulou K, Tsourouflis G, Gatzidou E, Kouraklis G, Theoharics S: Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity. Dig Dis Sci 2009, 54(2):282–291.
19. Freeman A, Hamid S, Morris L, Vowler S, Rushbrook S, Wight DG, Coleman N, Alexander G: Improved detection of hepatocyte proliferation using antibody to the pre-replication complex: an association with hepatic fibrosis and viral replication in chronic hepatitis C virus infection. J Viral Hep 2003, 10(5):345–350.
20. Marshall A, Rushbrook S, Morris LS, Scott IS, Vowler SL, Davies SE, Coleman N, Alexander G: Hepatocyte expression of minichromosome maintenance protein-2 predicts fibrosis progression after transplantation for chronic hepatitis C virus: a pilot study. Liver Transpl 2005, 11(4):427–433.
36. Gakipoupolou H, Korkolopoulou P, Levidou G, Thymara I, Saetta A, Piperi C, Givalos N, Vassilopoulou I, Ventouris K, Tsenga A, Barnia A, Dimopoulos MA, Agapitos E, Patouris E: Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. Br J Cancer. 2007, 97(8):1124–1134.

37. Scott IS, Heath TM, Morris LS, Rushbrook SM, Bird K, Fowler SL, Arends MJ, Coleman N: A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens. Br J Cancer. 2004, 90(5):1538–1540.

38. Kato K, Toki T, Shimizu M, Shiozawa F, Fuji S, Nikaido T, Konishi I: Expression of replication-licensing factors MCM2 and MCM3 in normal, hyperplastic, and carcinomatos endometrium: correlation with expression of Ki-67 and estrogen and progesterone receptors. Int J Gynecol Pathol. 2003, 22(4):334–340.

39. Dudderidge TJ, McCracken SR, Loddo M, Fanshawe TR, Kelly JD, Neal DE, Leung HY, Williams GH, Stoeber K: Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. Br J Cancer. 2007, 96(1):178–139.

40. Burger M, Denzinger S, Hartmann A, Wieland WF, Stoehr R, Oberrmann EC: MCM2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Br J Cancer. 2007, 96(1):1711–1715.

41. Kruger S, Thoms C, Stecker W, Muller-Kunert E, Bohle A, Feller AC: Prognostic value of MCM2 immunoexpression in stage T1 transitional cell carcinoma of the bladder. Eur Urol. 2003, 43(2):139–145.

42. Yang J, Ramnath N, Moshij KB, Aschi HL, Svede H, Alawi SJ, Huberman J, Geradts J, Brooks JS, Tan D: Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer. 2006, 6:203.

43. Hashimoto K, Araki K, Osaki M, Nakamura H, Tomita K, Shimizu E, Ito H: Minichromosome maintenance 2 and Ki-67 expression in human lung adenocarcinoma: prognostic implications. Pathobiology. 2004, 71(4):193–200.

44. Wejnati A, Pula B, Piotrowska A, Jethon A, Kujawa A, Kobierzycyk C, Ryj J, Podhorska-Okolow M, Dziegel P: Correlation of intensity of MT-I/II expression with Ki-67 and MCM-2 proteins in invasive ductal breast carcinoma. Anticancer Res. 2011, 31(9):3027–3033.

45. Gonzalez MA, Pinder SE, Callaghy G, Fowler SL, Morris LS, Bird K, Bell JA, Laskey RA, Coleman N: Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol. 2003, 21(3):4306–4313.

46. Shetty A, Loddo M, Fanshawe T, Prevost AT, Sainsbury R, Williams GH, Stoeber K: DNA replication licensing and cell cycle kinetics of normal and neoplastic breast. Br J Cancer. 2005, 93(1):295–300.

47. Wenymska B, Pula B, Muszynska-Bernhard B, Piotrowska A, Jethon A, Podhorska-Okolow M, Dziegel P, Jankowska R: Correlation between expression of metalloproteinase and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. Anticancer Res. 2011, 31(9):2833–2839.

48. Saydam O, Senol O, Schajii-Visser TB, Pham TV, Piersma SR, Steemmer-Rachamimov AO, Wudertinger T, Peerederman SM, Jimenez CR: Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas. J Proteome Res. 2009, 8(1):485–494.

49. Helfenstein A, Frahm SQ, Krams M, Drescoh W, Panwaresch R, Hassenpflug J: Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: distinction from enchondroma and identification of progressive tumors. Am J Clin Pathol. 2004, 122(6):912–918.

50. Schrader C, Janssen D, Klapper W, Siebmann JU, Meusers P, Birtinger G, Kneba M, Tiemann M, Panwaresch R: Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer. 2005, 93(8):939–945.

51. Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH: Replicative MCM2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol. 2001, 27(4):305–313.

52. Scott IS, Morris LS, Rushbrook SM, Bird K, Fowler SL, Burnet NG, Coleman N: Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology. Neuropathol Appl Neurobiol. 2005, 31(5):455–466.

53. Soling A, Sackewitz M, Vollmar M, Schaeabschmidt D, Jacob R, Holzhausen HJ, Rainow NG: Minichromosome maintenance protein 3 elicits a cancer-directed immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. Clin Cancer Res. 2005, 11(1):249–258.

54. Facetti A, Ranza E, Bencicetti E, Ceroni M, Tedeschi F, Nano R: Minichromosome maintenance protein 7: a reliable tool for glioblastoma proliferation index. Anticancer Res. 2006, 26(2A):1071–1075.

55. Facetti A, Ranza E, Greccci I, Bencicetti E, Ceroni M, Morbini P, Nano R: Immunohistochemical evaluation of minichromosome maintenance protein 7 in astrocytoma grading. Anticancer Res. 2006, 26(5A):3513–3516.

56. Erkan EP, Strobel T, Lewandrowski G, Tannous B, Madlener S, Czech T, Saydam N, Saydam O: Depletion of minichromosome maintenance protein 7 inhibits glioblastoma multiforme tumor growth in vivo. Oncogene 2013. doi:10.1038/onc.2013.423. [Epub ahead of print].

57. Kobierzycyki C, Pula B, Skiba M, Jablonska K, Latkoski K, Zabel M, Nowak-Mark witz E, Spaczynski M, Kedzia W, Podhorska-Okolow M, Dziegel P: Comparison of minichromosome maintenance proteins (MCM-3, MCM-7) and metalloproteinase (MT-I/II, MT-III) expression in relation to clinicopathological data in ovarian cancer. Anticancer Res. 2013, 33(12):5375–5383.

58. Toschi L, Bravo R: Changes in cyclin/proliferating cell nuclear antigen distribution during DNA repair synthesis. J Cell Biochem. 1988, 30(7):1623–1628.

59. Ha SA, Shin SM, Namkoong H, Lee H, Cho GH, Huv SY, Kim TE, Kim JW: Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res. 2004, 10(24):8386–8395.

60. Parkins CS, Darling JL, Gill SS, Reverte T, Thomas DG: Cell proliferation in serial biopsies through human malignant brain tumours: measurement using Ki67 antibody labelling. Br J Neurosurg. 1991, 5(3):289–298.

61. Torp SH: Diagnostic and prognostic role of Ki67 immunoassaying in human astrocytomas using four different antibodies. Clin Neuropathol. 2002, 21(6):252–257.

http://www.biomedcentral.com/1471-2407/14-526